INTRODUCTION: The introduction of an HPV immunisation programme in England should result in a significant reduction in the prevalence of vaccine type infections in young women. Here we describe type-specific HPV prevalence in three samples of the young female population in England, prior to the beginning of mass immunisation in 2008. METHODS: Residual vulva-vaginal swab samples from females aged under 25 years undergoing chlamydia testing as part of the National Chlamydia Screening Programme (NCSP) or Prevention of Pelvic Infection (POPI) trial were collected from sites across England, together with available demographic and sexual behaviour data. Residual samples were screened for HPV infection using the Hybrid Capture 2 (hc2) HPV DNA Test, including the high-risk (HR) and low-risk (LR) probes. Hc2 positive samples were genotyped using the Roche Linear Array (LA) HPV Genotyping Test. RESULTS: A total of 3829 samples were included: 2369 from 16 to 24 year old NCSP participants, 275 from 13 to 15 year old NCSP participants and 1185 from 16 to 24 year old POPI participants. Variations in HPV prevalence between and within the different samples followed a pattern largely consistent with differences in sexual behaviour. The prevalence of total HR HPV infection, of HPV 16 and/or 18 (16/18) infection and of five HR HPV types closely related to HPV 16/18 (HPV 31, 33, 45, 52 or 58) amongst 16-24 year old NCSP participants was 35% (95% CI 33-37%), 18% (95% CI 16-19%), and 16% (95% CI 14-18%), respectively. Risk of HR HPV infection increased with age during the teen years and was higher in women who reported two or more sexual partners in the last year and in women with chlamydia infection. Approximately half of women with HPV 16/18 infection also had another non-vaccine HR HPV type present. CONCLUSIONS: Prior to HPV immunisation, there was a high prevalence of HPV infections in the lower genital tract of young, sexually active females in England. The overall, type-specific, and multiple infection prevalence closely reflected age and sexual activity. These data provide a baseline against which the early impact of HPV immunisation on the prevalence of HPV 16/18 and closely related types in young women can be measured, in order to inform immunisation and cervical screening policies.
INTRODUCTION: The introduction of an HPV immunisation programme in England should result in a significant reduction in the prevalence of vaccine type infections in young women. Here we describe type-specific HPV prevalence in three samples of the young female population in England, prior to the beginning of mass immunisation in 2008. METHODS: Residual vulva-vaginal swab samples from females aged under 25 years undergoing chlamydia testing as part of the National Chlamydia Screening Programme (NCSP) or Prevention of Pelvic Infection (POPI) trial were collected from sites across England, together with available demographic and sexual behaviour data. Residual samples were screened for HPV infection using the Hybrid Capture 2 (hc2) HPV DNA Test, including the high-risk (HR) and low-risk (LR) probes. Hc2 positive samples were genotyped using the Roche Linear Array (LA) HPV Genotyping Test. RESULTS: A total of 3829 samples were included: 2369 from 16 to 24 year old NCSP participants, 275 from 13 to 15 year old NCSP participants and 1185 from 16 to 24 year old POPI participants. Variations in HPV prevalence between and within the different samples followed a pattern largely consistent with differences in sexual behaviour. The prevalence of total HR HPV infection, of HPV 16 and/or 18 (16/18) infection and of five HR HPV types closely related to HPV 16/18 (HPV 31, 33, 45, 52 or 58) amongst 16-24 year old NCSP participants was 35% (95% CI 33-37%), 18% (95% CI 16-19%), and 16% (95% CI 14-18%), respectively. Risk of HR HPV infection increased with age during the teen years and was higher in women who reported two or more sexual partners in the last year and in women with chlamydia infection. Approximately half of women with HPV 16/18 infection also had another non-vaccine HR HPV type present. CONCLUSIONS: Prior to HPV immunisation, there was a high prevalence of HPV infections in the lower genital tract of young, sexually active females in England. The overall, type-specific, and multiple infection prevalence closely reflected age and sexual activity. These data provide a baseline against which the early impact of HPV immunisation on the prevalence of HPV 16/18 and closely related types in young women can be measured, in order to inform immunisation and cervical screening policies.
Authors: Krystle A Lang Kuhs; Paula Gonzalez; Ana Cecilia Rodriguez; Leen-Jan van Doorn; Mark Schiffman; Linda Struijk; Sabrina Chen; Wim Quint; Douglas R Lowy; Carolina Porras; Corey DelVecchio; Silvia Jimenez; Mahboobeh Safaeian; John T Schiller; Sholom Wacholder; Rolando Herrero; Allan Hildesheim; Aimée R Kreimer Journal: J Infect Dis Date: 2014-06-23 Impact factor: 5.226
Authors: Sara L Bissett; Anna Godi; Maxime J J Fleury; Antoine Touze; Clementina Cocuzza; Simon Beddows Journal: J Virol Date: 2015-05-20 Impact factor: 5.103
Authors: Anna Godi; Alessandra Facchetti; Sara L Bissett; Clementina Cocuzza; Elizabeth Miller; Simon Beddows Journal: J Virol Date: 2015-12-30 Impact factor: 5.103
Authors: Catharina Johanna Alberts; Maarten F Schim van der Loeff; Mary R Papenfuss; Roberto José Carvalho da Silva; Luisa Lina Villa; Eduardo Lazcano-Ponce; Alan G Nyitray; Anna R Giuliano Journal: Sex Transm Dis Date: 2013-06 Impact factor: 2.830
Authors: Eve Draper; Sara L Bissett; Rebecca Howell-Jones; Pauline Waight; Kate Soldan; Mark Jit; Nicholas Andrews; Elizabeth Miller; Simon Beddows Journal: PLoS One Date: 2013-05-01 Impact factor: 3.240
Authors: Zongyuan Chen; William R Abrams; Eran Geva; Claudia J de Dood; Jesús M González; Hans J Tanke; R Sam Niedbala; Peng Zhou; Daniel Malamud; Paul L A M Corstjens Journal: Biomed Res Int Date: 2013-02-14 Impact factor: 3.411
Authors: Karl Ulrich Petry; Alexander Luyten; Annika Justus; Angelika Iftner; Sarah Strehlke; Axel Reinecke-Lüthge; Elisabeth Grunwald; Renate Schulze-Rath; Thomas Iftner Journal: BMC Infect Dis Date: 2013-03-13 Impact factor: 3.090